LONDON, Feb. 10 /PRNewswire/ -- Microdosing or Phase 0 clinical testing has been gaining acceptance and might become an imperative phase of the drug development process in the years to come. The emergence of niche capability providers in preclinical testing and technology dependence is also expected to result in numerous partnerships and alliances, fuelling growth opportunities in this sector.
"There is every reason to believe that the solution for faster screening of candidates and increasing pressure on costs is gaining momentum in the right direction," notes Frost & Sullivan (http://www.pharma.frost.com) Senior Research Analyst V. Sriram. "The compelling advantages of microdosing present it as a potential remedy for big pharma's maladies regarding declining returns from investments in drug development."
Alliances between contract research organisations (CROs) in the U.S. and Europe have not historically been common. This is due to several factors including the industry's strong growth and relatively low technology demands for clinical testing. However, developments in microdosing should see a number of opportunities being investigated.
Consolidation within the CRO space has led to concerns over the quality of service and attention to detail. Companies must however ensure the quality of their services to maintain their bargaining power with the pharmaceutical companies.
"CROs face the challenge of competitively aligning their services to meet customer needs in order to overcome the threat of losing their stronghold and loyalty," comments Sriram.
Developing the technological know-how and expertise on niche capabilities will help CROs retain t
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved